PRRUF
What one share of Immutep Limited holds
Pharmaceutical Preparations
Immutep is a late-stage biotechnology company developing novel LAG-3 related immunotherapies for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3).
Immutep Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-06-30; the balance sheet is as of 2025-06-30.
| Sales | $0.92 |
|---|---|
| Profit | −$5.46 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$5.52 |
| Cash and investments | $6.06 |
| Book value | $12.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $5.36 | −$4.38 | $0.01 | −$3.52 | — | $9.42 |
| 2021 | $1.00 | −$7.52 | $0.00 | −$4.44 | — | $14.68 |
| 2022 | $1.16 | −$5.50 | $0.00 | −$5.18 | — | $15.00 |
| 2023 | $0.78 | −$6.02 | $0.01 | −$5.34 | — | $15.32 |
| 2024 | $0.86 | −$4.66 | $0.00 | −$3.80 | — | $17.42 |
| 2025 | $0.92 | −$5.46 | $0.00 | −$5.52 | — | $12.92 |